The use of antipsychotics to manage challenging behaviour in adults with intellectual disability is widespread but controversial and lacking in evidence. There is a perception that antipsychotics used in this context can be reduced or discontinued and this has been a major focus of recent national policy. However, such an intervention risks harm as well as having potential benefits. We reviewed the available evidence and found that antipsychotics can be reduced or discontinued in a significant proportion of adults who use them for challenging behaviour, though not always without adverse reactions. There is a group who display behavioural deterioration on antipsychotic reduction that prevents discontinuation; predictors of poor response could not be reliably identified. Given the relative lack of data and methodological limitations of the available studies, we cannot draw firm conclusions to inform a population level approach to this issue. Antipsychotic medication used for behaviour should be reviewed regularly and an individualised approach taken to treatment.
Introduction
Intellectual disability (ID) is a lifelong condition of impaired cognitive function and deficit in adaptive skills. 1 Antipsychotic medication is often prescribed to adults with ID to manage challenging behaviour in the absence of severe mental illness. 2, 3 Challenging behaviour is a non-specific term used to describe any behaviour that may threaten the physical safety of a person with ID or those around them, or that is likely to limit access to ordinary community facilities. 4 It includes presentations such as aggression, self-injury, and property destruction. The prevalence of challenging behaviour in those with ID is typically quoted as 10-15%, 5, 6 although that this might be an underestimate. 2, 7 Interventions aimed at reducing the frequency or degree of challenging behaviour must recognise the array of biological, psychological, and social factors that can underlie the development and maintenance of behaviour disturbance. 8 There is very limited evidence that antipsychotics are effective in reducing challenging behaviour in adults with ID. 9, 10 The NICE guideline on behaviour that challenges recommends a stepped approach to assessment and a central role for psychosocial strategies in management, with antipsychotic medication being used only in certain circumstances and continued only when benefit is clearly demonstrated (panel 1). 11 There has been longstanding criticism of the use, and perceived over-use of antipsychotic medication in people with ID. 12, 13 Professionals and care providers are under close scrutiny following the exposure of systemic abuse of people with ID and complex challenging behaviours at Winterbourne View Hospital, and the prescription of psychotropic medication to people with ID has achieved widespread coverage in the lay and specialist media. 14, 15 Transforming Care, the UK Government response to the scandal at Winterbourne View, restated concerns about the inappropriate use of psychotropic medication in this group. 16 These concerns were substantiated by two studies of psychotropic prescribing to people with ID in UK primary care. 2, 17 NHS England have issued a 'Call to Action,' (https://www.england.nhs.uk/2015/07/urgent-pledge/), a national drive to reduce antipsychotic prescription rates in people with ID.
Challenging behaviour often persists and those who are prescribed antipsychotic medication tend to remain on it for long periods. 18, 19 Reasons might include; favourable drug response; lack of efficacy or availability of alternative (psychosocial) treatments; infrequent or ineffectual medication review; and lack of professional or caregiver confidence in making medication changes for fear of the consequence.
Long-term antipsychotic use is not without risks and adverse effects associated with antipsychotic drugs include movement (extra-pyramidal) side-effects, autonomic disturbance, and endocrine and metabolic disorders. 20 Some can cause sedation and those with a high-degree of anti-cholinergic activity might impair cognition, especially when used in combination with other anti-cholinergic agents. 21, 22 People with ID are often considered at greater risk of developing such side-effects 23 although there has been relatively little research on the side-effect profile of psychotropic drugs specifically in people with ID and few studies directly compare side-effect rates in people with and without ID.
It is desirable to reduce antipsychotic medication where possible. There is evidence of the effect of antipsychotic discontinuation in adults with average intelligence who take antipsychotics for severe mental illness 24, 25 and older adults prescribed antipsychotics for neuropsychiatric symptoms in dementia. 26, 27 Antipsychotic discontinuation in children with autism spectrum disorders who take antipsychotics for behaviour disorder has also been studied, although primarily with the intention of testing the efficacy of long-term antipsychotic use rather than investigating the consequences of planned reduction. [28] [29] [30] As yet there has been no thorough review of the effect of antipsychotic discontinuation in those with ID and the focus of existing discontinuation studies, the participants included, and outcomes measured mean that results might not generalize to those with ID who take antipsychotics.
We conducted a systematic review of the evidence concerning the outcome of reduction or discontinuation of long-term antipsychotic medication used for management of challenging behaviour in adults with ID.
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Methods
Electronic databases (Medline, EMBASE, PsycINFO, Cochrane, CINAHL Plus) were searched for relevant articles published in any language between 1 st January 1990 and 1 st March 2016. Search terms for 'intellectual disability', 'antipsychotic medication' and 'reduction/discontinuation' and their synonyms were combined, with relevant MeSH terms also included (appendix A). Reference lists of included studies were checked and their citations were tracked using the Science Citation Index Expanded to supplement the original search. The review protocol was registered with PROSPERO (2015:CRD42015019917).
We included studies published in peer-reviewed journals and all study designs, including individual case studies, but excluded non-peer reviewed articles including letters, meeting abstracts, and dissertations.
Adults (>18 years) with any degree of ID of any aetiology were included. ID was authordefined and expected to conform to ICD/DSM criteria. Participants could have any physical or psychiatric co-morbidity, although those studies where a significant number had psychotic disorders were excluded. Studies conducted in community or institutional settings were included.
Participants must have been taking an antipsychotic regularly for at least 12 weeks before the intervention. Studies reporting reduction or discontinuation of either first-and secondgeneration antipsychotics were included. The antipsychotic must have been used primarily to manage challenging behaviour, rather than to treat mental illness. Challenging behaviour was author-defined.
The reduction or discontinuation of antipsychotic medication must have been the main intervention. Reduction was defined as a sustained change in antipsychotic to a lower dose and discontinuation as the complete cessation of antipsychotic medication. Any schedule of reduction or discontinuation was permitted. Simultaneous interventions, including adjustment of other classes of medication and psychotherapeutic interventions, were acceptable but studies that report the substitution of one antipsychotic for another were not included.
The primary outcome was the proportion of participants achieving dose reduction or discontinuation without drop-out or reinstatement of the antipsychotic. Studies that report average dose changes or where change in antipsychotic use could not be differentiated from change in other psychotropic drugs were excluded.
Secondary outcomes measures included change in behaviour, physical health, mental health, cognitive or adaptive functioning, and quality of life in those who reduced or discontinued antipsychotic medication.
All citations were imported into an EndNote library. Duplicates were removed in a two-stage process using the software function and then manually by checking titles. The titles of the remaining citations were screened against the inclusion criteria. Abstracts of the remaining citations were reviewed allowing the exclusion of further studies. When the abstract indicated the paper potentially met inclusion criteria, the full text was reviewed.
Included studies were categorised according to the hierarchy published by the Centre for Evidence-Based Medicine. 31 A separate evaluation of the quality of each study was made focusing on limitations and biases.
Results

Study characteristics
The initial search yielded a total of 1,018 citations and of these twenty-one studies met inclusion criteria (figure 1). Included studies are summarised in table 1. Studies excluded after full-text review are listed in appendix B.
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We found one (open) RCT, the results of which are reported in two papers; 32,33 one caseseries 34 ; one single-case report. 35 The remainder of studies were observational studies, some of which included control groups. [36] [37] [38] [39] Fifteen studies were conducted in the USA. Five European studies were included and one from Australasia. Thirteen studies included only participants living in institutions, two studies included only those living in community settings, five studies report on participants living in a range of settings, and in one study the living arrangements of participants are not reported.
Studies reported the outcome of antipsychotic discontinuation or reduction in 1,027 participants in total. Discontinuation practices included dose-reduction programmes and that were under clinician control. In five studies reduction/discontinuation of antipsychotics was according to formal research protocol.
Details of participants are incompletely reported in several studies. Mean age of participants in studies ranged from 24 to 50 years, with the one case report describing outcome of antipsychotic discontinuation in a 74 year old. There was a predominance of men (approximately 2/3 of those undergoing antipsychotic reduction and discontinuation) and just over 80% had severe-profound ID. Participants were prescribed antipsychotics for challenging behaviour; in almost all cases the nature of the challenging behaviour was not given. A minority in each study had diagnosed co-morbid mental illness. In studies where indication for antipsychotic prescription was not clearly given, the authors clearly allude to challenging behaviour. Most of the antipsychotics were first generation agents.
Outcomes of reduction or discontinuation of antipsychotic medication used for behaviour Success of attempts to reduce or discontinue antipsychotic medication
Ten studies describe the outcome of reduction or discontinuation of antipsychotic medication as the proportion of the intervention group who were maintained on a lower dose or achieved drug discontinuation at follow-up (ranging from 3 months to over 10 years). 32,38,40- 47 The proportion of participants maintained on a reduced dose was between 19% and 83%, discontinuation of antipsychotics ranged from 4% to 74%, the proportion unsuccessful in attempts to reduce or discontinue antipsychotics was between 0% and 96% (table 2) . In several cases, reporting of the study is such that it is not possible to distinguish three groups accurately. Due to the study designs we are unable to obtain a summary measure of the successful reduction or discontinuation of antipsychotics, but taken together, these studies have value in providing broad estimates of rates of reduction or discontinuation that might be achieved in a clinical setting.
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Effect of reduction or discontinuation of antipsychotics on behaviour
Six studies report the effect of antipsychotic reduction or discontinuation on participant behaviour. 32, 39, 43, 44, 47, 48 Behavioural outcome measures ranged from validated instruments to colloquial reports (Appendix C).
[ Table 3 near here] Ahmed and colleagues found no difference in challenging behaviour in the group who discontinued or reduced antipsychotic medication by ≥50% and the control group who underwent no medication change (p>0·05, data not given). 32 They also report behaviour outcomes of the 'failure' group, that is, those who were randomised to the drug reduction arm but who did not discontinue or significantly reduce dose. This group did not demonstrate worsening of overall behaviour and the decision to arrest dose reduction or reinstate medication was found to be related to setting rather than individual variables, including having fewer full-time and senior staff, lower levels of staff training, and more restrictive environmental features.
deKuijper examined baseline and follow-up differences (12 weeks after planned discontinuation) in carer rated total Aberrant Behaviour Checklist (ABC) score in their cohort. 47 In the group that completed antipsychotic discontinuation, the mean total ABC score reduced from 47 (sd 27) to 37 (sd 29) (p=0·03). Carer ratings of target behaviour on the Visual Analogue Scale (VAS) did not change (mean 6·4 (sd 1·4) vs 6·5 (sd 1·4), p=0·76). The subgroup who reduced antipsychotic dose but did not progress to full discontinuation also showed a statistically significant decline in mean ABC score from baseline to follow-up (62 (sd 27) vs 50 (sd 36), p=0·03), although with a simultaneous increase in severity of challenging behaviour measured by the VAS (6·4 (sd 1·4) vs 5·8 (sd 1·6), p=0·03). Thus, the findings of the VAS potentially contradict the improvement in behaviour measured by the ABC. The authors suggest bias in the VAS scores introduced by caregivers who have the expectation of deterioration following antipsychotic reduction as a possible explanation. A further paradox in this study is that those in the group who reduced but did not discontinue antipsychotics were said not to have progressed to discontinuation "if there was a significant behavioural worsening according to the clinician's judgement", suggesting that this group is, in fact, defined by subjective deterioration in behaviour.
May et al. monitored challenging behaviour of a group of adult men with severe-profound ID over the course of antipsychotic withdrawal to discontinuation using frequency counts. 48 Using a very slow regime of antipsychotic taper and following individuals for at least 3 years, distinct groups became apparent. Five individuals (22%) showed progressive improvement in behaviour coinciding with antipsychotic reduction, 9 (39%) demonstrated transient worsening, and 9 (39%) experienced persistent behavioural worsening requiring prescription of either antipsychotics or other psychotropics. Those who experienced a progressive improvement on antipsychotic withdrawal tended to demonstrate greater baseline frequency of challenging behaviour. However, the study was under-powered for observed differences to reach statistical significance.
Swanson measured total ABC score at baseline, three subsequent time-points during antipsychotic dose reduction, and after discontinuation. 39 Total ABC score increased during withdrawal before falling.
Branford describes the outcome of antipsychotic reduction attempts in 123 patients. 44 One quarter achieved discontinuation without any deterioration in behaviour, 42% experienced deterioration in behaviour necessitating re-prescribing or attenuation of dose reduction. Behaviour change of the remaining individuals (33%) was not reported. Janowsky et al. report outcome at three months following antipsychotic reduction attempts in a group of 138 participants. 45 Whilst 60% tolerated discontinuation, the remainder had a "significant increase in maladaptive target symptoms" which required antipsychotic represcribing or dose increase. The same authors report a follow-up study of 49 of those who failed attempts to discontinue antipsychotic medication; 96% experienced behavioural relapse in future attempts to discontinue medication. 46 Effect of reduction or discontinuation of antipsychotics on physical health
Ten studies reported physical health outcomes resulting from antipsychotic reduction or discontinuation. 32,35,37-39,47,49-52 Below we report physical health outcome grouped by theme.
Movement effects
Several studies that reported movement effects of antipsychotic reduction or discontinuation used the Dyskinesia Identification System: Condensed User Scale (DISCUS), a scale specifically developed to measure abnormal movements in individuals with ID. 53 Fifteen items relating to movement of different body regions are rated from 0 (not present) to 4 (severe). Categorical definitions for clinically-relevant dyskinesia have been developed based on the total DISCUS score. 54, 55 Wigal et al compared change in DISCUS score at baseline and 10-month follow-up between four groups defined by increase in antipsychotic dose, no change, antipsychotic dose reduction by <25%, and antipsychotic dose reduction ≥25% (but not matched by any other characteristic). 37 Follow-up mean DISCUS score increased in all groups apart from the dose increase group, with the degree of dose reduction being positively correlated with increase in DISCUS score (r=0·506, p<0·001). Employing a categorical definition of dyskinesia (at least a 'mild' rating of abnormal movements in at least two body regions, or at least a 'moderate' rating of abnormal movements in one body region), 55 the authors found the rate of dyskinesia increased from 30% at baseline to 60% at follow-up in the group who reduced medication by >25%, but remained stable in the groups who reduced medication by a lesser percentage or who underwent no dose change.
A later study by the same group reports a small controlled study of 30 individuals with nested controls defined by antipsychotic dose changes. 38 63% of those who discontinued antipsychotic medication developed tardive dyskinesia compared with 29% of those undergoing dose reduction and none of the controls or those who underwent antipsychotic dose increase or no change.
A third study by this group reports results of antipsychotic discontinuation in 40 people and compare DISCUS scores with a control group at several time-points. 39 The participants are further subdivided by anticonvulsant use, producing 4 groups in total. Mean DISCUS score increased after antipsychotic discontinuation in the group taking antipsychotics alone but not in the group who received concomitant treatment with anticonvulsant medication, raising the possibility of a mitigating effect of anticonvulsants in reducing discontinuation reactions.
Ahmed et al found total DISCUS score was significantly increased at 6 month follow-up in the group who discontinued antipsychotics or underwent ≥50% dose reduction compared with controls (p<0·01). 32 The DISCUS score in the intervention group fell between month 5 and 6, possibly indicating the start of a return to baseline.
The concept of a 'transient withdrawal dyskinesia' is developed in three studies by Newell et al who prospectively monitored individuals undergoing planned antipsychotic dose reduction to discontinuation. [49] [50] [51] The authors investigated change in movement disorder over time with DISCUS rating and by using proxies for movement abnormalities. The first investigated lip movements associated with dyskinesia and demonstrated changes in quality and quantity of resting lip motion over the course of antipsychotic reduction and discontinuation that tended to revert to the pre-reduction state at follow up 6-24 months after discontinuation. 49 In the second study, the authors again report change in DISCUS score; mean total DISCUS score increased from 3·4 at baseline to 10·7 at peak withdrawal (p<0·001), before falling to approximate baseline values at follow-up (mean follow-up DISCUS 3·5, p=NS). Rates of tardive dyskinesia showed a similar pattern, increasing from 31% at baseline to 85% at peak withdrawal, and then dropping to 38% at follow-up. 51 Data presented in the third of these studies reports postural stability as a measure of movement disorder. 50 Indices of postural stability and body motion changed significantly over the course of antipsychotic withdrawal and returned to baseline levels by follow-up. Mean total DISCUS increased from 3·5 at baseline (range 0-11), to 11·1 at peak withdrawal (range [3] [4] [5] [6] [7] [8] [9] [10] [11] [12] [13] [14] [15] [16] [17] [18] [19] [20] [21] [22] , and 3·8 at follow-up (range 0-11) (p<0·01 for difference over time). This study extends the analysis by reporting a positive association between higher baseline levels of movement symptoms and the degree of withdrawal-associated dyskinesia, thereby giving some indication of people who might be more prone to develop problematic dyskinesia on medication reduction.
deKuijper et al report movement side-effects as a composite of clinician-assessed Parkinsonism, akathisia, and extra-pyramidal side-effect ratings. 47 Reporting of this outcome is incomplete but there was little change in average movement side-effect score between baseline and at the point of antipsychotic discontinuation in those who completed withdrawal (baseline score 2·8, follow-up 3·0, p not given).
Autonomic function
Despite disturbance of autonomic function being a known side-effect of antipsychotic drugs, only two studies reported the autonomic effects of their reduction or discontinuation. 35,47 deKuijper 47 used the Scale Outcomes Parkinson's disease-Autonomic symptoms (SCOPA-AUT) to assess autonomic adverse events at baseline and following reduction or discontinuation of antipsychotics. 56 Both the group achieving discontinuation and the group who underwent dose reduction short of complete discontinuation showed significantly decreased SCOPA-AUT scores at 12 week follow-up (in the discontinuation group mean SCOPA-AUT changed from 6·0 to 3·6, p<0·01; in the dose reduction group mean SCOPA-AUT changed from 6·0 to 4·9, p<0·01) indicating a lower burden of autonomic symptoms and a dose-response relationship.
In a case report, Orfan and Kolski describe the outcome of fluphenazine withdrawal in a 74 year old woman with ID who received the drug for behaviour control. 35 The patient developed "severe and debilitating" rhinorrhoea following antipsychotic discontinuation.
Weight / metabolic parameters
Ahmed et al compared weight change between a group who discontinued or reduced antipsychotic dose by ≥50% and a control group who underwent no medication change. 32 Those in the intervention group lost an average of 2·3kg at 6 months, although this was not statistically different from weight change observed in controls (data not given, p>0·05).
deKuijper reports change in weight, BMI, and several metabolic parameters in a subgroup of participants who achieved antipsychotic discontinuation and remained antipsychotic free at 12 weeks. 52 Waist circumference, weight, and BMI were all significantly reduced at follow-up compared with baseline (waist circumference 93·2cm vs 88·8cm, p<0·001; weight 68·7kg vs 65·2kg, p=0·02; BMI 25kg/m 2 vs 23·66kg/m 2 , p=0·006). Systolic, but not diastolic blood pressure also showed a significant fall (systolic 129mmHg vs 122mmHg, p=0·02; diastolic 80mmgHg vs 75mmHg, p=NS). Laboratory markers of the metabolic syndrome (plasma triglycerides, HDL, and fasting glucose) did not change significantly, although this might be a reflection of the relatively short duration of follow-up.
Effect of reduction or discontinuation of antipsychotics on mental health
No studies reported the effect of reduction or discontinuation of antipsychotics on the mental health of participants.
Effect of reduction or discontinuation of antipsychotics on cognitive/adaptive functioning
Four studies reported impact of reduction or discontinuation of antipsychotics on cognitive or adaptive function. In a small controlled study, Carpenter and colleagues report the effect on performance in a standardised computer-based cognitive test in which participants are required to match colours. 36 All of those undergoing antipsychotic dose reduction or discontinuation demonstrated improved performance on the test compared with none of those with no medication change or not on an antipsychotic drug (number of attempts to reach 4 consecutive correct responses reduced by average of 29% in withdrawal group (range 13·8-53·5%) and by 0.4% in control group (range 0·3% -0·7%); percentage of correct responses increased by average of 10% in withdrawal group (range 2·7% -19·7%) but declined by 1·5% in controls (range 1·3% --4·9%); statistical tests not performed).
Gedye reports the results of a small case series (n=4). 34 All had demonstrated cognitive decline and been diagnosed clinically with dementia, at an average age of 42 years. Reduction and later discontinuation of antipsychotic medication resulted in substantial and sustained clinician-rated improvement in overall cognitive and adaptive function such that the diagnosis of dementia was no longer applicable.
Ahmed et al 32 directly observed participant behaviour for a random 1·5 hour period three times a month during their 6 month study and collated the amount of time participants spent in each of several pre-defined activities, including a measure of engagement in the activity. Full results are not reported but the authors state that the group who discontinued antipsychotics or had at least 50% dose reduction spent significantly more time engaged in activity than controls (p<0·05). Additional data obtained in the same study focus specifically on responsiveness to staff interaction. 33 No difference in likelihood of response to staff interaction was found between the groups, probably as a high baseline response was recorded.
Predictors of successful antipsychotic reduction or discontinuation
As part of a separate search, we identified studies that report factors associated with success of attempts to reduce or discontinue antipsychotic reduction (table 3) . Relatively good evidence shows that those who have previously failed attempts to reduce antipsychotic medication are poor candidates for further attempts to stop medication. 46 Studies tend to be in agreement that those on a lower baseline antipsychotic dose are more likely to have successful withdrawal. 47, 48, 57, 58 Other predictors of successful withdrawal attempts are less clear and are sometimes conflicting between studies (e.g. gender). Those with a high level of psychopathology (whether psychotic or not) seem to be more likely to relapse when an antipsychotic is withdrawn; 57, 59 these may be people with co-morbid mental illness which deteriorates when an their medication is reduced. The use of concomitant psychotropics (including antiepileptic drugs) has been shown to be of benefit in facilitating antipsychotic withdrawal attempts, 59 although this is not a consistent finding. 48, 57 Discussion A significant proportion of individuals in whom a concerted effort was made to reduce antipsychotic drugs achieved discontinuation or dose reduction. This suggests that clinicians can reasonably attempt to reduce antipsychotics in patients who are prescribed them for challenging behavioural. However, it is also the case that many of those in whom attempts were made to reduce or discontinue antipsychotic medication could not tolerate reduction and required re-prescribing. Stevenson and colleagues, writing in the aftermath of the restrictions imposed on the use of the first-generation agent thioridazine in 2000, contested that wide-scale antipsychotic withdrawal in this group is likely to cause serious harm, including precipitating increases in behaviour problems and mental ill-health. 60 Overall results from studies that report behavioural outcomes are inconclusive. Both deKuijper et al 47 and Ahmed et al 32 report no change, or even improvement in behaviour after antipsychotic discontinuation, although those whose behaviour deteriorated did not complete the withdrawal programme. Other studies report between 40% and 96% of those undergoing dose reduction experience significant behavioural deterioration which could persist for several years. [44] [45] [46] 48 None of the included studies investigated mechanisms underlying behavioural deterioration following antipsychotic reduction or discontinuation. Hypotheses related to a pathophysiological discontinuation syndrome include; onset of super-sensitivity psychosis; cholinergic and/or adrenergic rebound; and emergence of movement side-effects such as withdrawal dyskinesia or tardive akathisia. 61 In all cases, the impact of symptoms may be greater in people with ID due to limitations in understanding and communicating distress verbally, which may then find expression as challenging behaviour. Slow taper of antipsychotic medication has been advocated in order to minimise the risk of these discontinuation effects 62 although the only study that compared rates of antipsychotic taper did not find any advantage in stopping the medication over a period of longer than 14 weeks. 47 One of the most consistent findings of the review is the transient increase in dyskinesia that accompanied antipsychotic reduction or discontinuation associated with the use of both first-and second-generation agents. 63 Dyskinesia on antipsychotic reduction appears to be proportionate to the degree of dose reduction and may persist for several months. A return to baseline measures of dyskinesia was noted in studies employing longer follow-up periods, suggesting that it remits over time.
Weight loss and some improved markers of the metabolic syndrome were noted when antipsychotics were reduced or discontinued. 32, 52 This is an important consideration in adults with ID who are more likely to be obese than peers of average intelligence 64 , and less likely to eat a balanced diet or achieve minimum recommended physical activity targets. 65 Antipsychotic medication may reduce cognitive ability in people with ID, either due to increased somnolence and sedation 66, 67 or their anti-cholinergic properties. Where change in cognition was investigated there was some evidence of improvement in those who reduced or discontinued antipsychotics. This warrants further attention given that reductions in cognitive capacity might negatively impact the success of psychosocial management of challenging behaviour and interfere with habilitation programmes.
Limitations of existing research and directions for future research
A major finding of the review is that current literature on the feasibility and outcome of antipsychotic withdrawal in people with ID is lacking in volume, quality and scope. Critical appraisal (table 1) revealed trials including small numbers of participants, selection bias and use of convenience samples, lack of control groups and of blinding, lack of standardised or validated outcome measures, and incomplete outcome reporting or statistical testing. The studies were often naturalistic and the intervention to reduce or discontinue antipsychotics was not well described. The length of follow-up was often short and may have been insufficient to capture some important outcomes. Studies may have included other simultaneous interventions that were not reported and could have confounded the results. No studies addressed the effect of reduction or discontinuation of antipsychotics on participant's mental health, despite withdrawal of antipsychotics having been associated with new-onset psychotic symptoms even in those without previous psychosis. 68 These significant methodological shortcomings limit the internal and external validity of the results and the strength of conclusions we are able to draw.
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Systematic review -strengths and limitations
This is the first study of which we are aware that has attempted to consolidate current knowledge on this topic. Our search strategy was comprehensive, conducted according to a pre-defined protocol, and undertaken in several databases. We included all types of outcome measure in order to present a broad analysis.
There are some limitations of our review. We chose to exclude studies published before 1990 as we felt that the relatively rapid changes in understanding and care of people with ID make it difficult to generalise results of earlier studies to current practice. Despite this date limit, a number of studies that we included were conducted in large residential institutions for people with ID. Most studies include a high proportion of people with severe-profound ID who constitute only a minority of the total intellectually disabled population.
Most people in included studies were taking a first-generation antipsychotic drug. This might limit the relevance of the review findings although there is evidence that a significant proportion of people taking antipsychotics still receive first-generation agents. 69 
Conclusions and implications for practice
Antipsychotics are likely to have a role in the multi-modal management of certain cases of challenging behaviour in people with ID but clinicians must respond to the prevailing attitude that these drugs have too often been used indiscriminately and for too long. Evidence-based practice guidelines and quality indicators have been developed to improve antipsychotic prescribing for challenging behaviour. 11, [70] [71] [72] These focus on the holistic assessment and management of challenging behaviour and the initiation of antipsychotic medication, rather than addressing antipsychotic discontinuation. There remains relatively little information to guide practice in reducing or discontinuing antipsychotics in the cohort who are already taking these drugs.
In terms of predictors of successful or unsuccessful reduction or discontinuation of antipsychotics, setting and carer characteristics (as well as some individual traits) were shown to be important consistent with previous research. Working conditions, staff experience, and attributions about challenging behaviour can influence how behaviour is reported and how it is managed. [73] [74] [75] Where psychotropic medication is used, carers often report inadequate training and a desire for more information. 76, 77 These deficiencies in knowledge and skills can act as a barrier to appropriate monitoring of antipsychotics in this group, particularly as clinicians are often heavily reliant on third-party reports of drug effects. 78 Living environment is similarly important in influencing prescribing; a four-fold difference in rates of antipsychotic prescription for behaviour has been demonstrated between those living in institutions and those residing in family homes, despite no underlying difference in the rates of behaviour disorder. 79 Clearly, any attempt to transform antipsychotic prescribing to people with ID must recognise the wider elements that may directly influence drug use and which individual clinicians have little power to change. 80 This review exposes a gap between the available evidence and the national policy drive to reduce antipsychotic prescribing to people with ID. We are not able to recommend a routine programme of antipsychotic discontinuation in people with ID who use the drugs for challenging behaviour and advocate a measured response according to published guidelines. 72 As contextual factors are important, commissioning of appropriate provider services and support for carers is paramount. No amount of goodwill will be sufficient to drive a change in the current status quo unless a systems approach to prescribing is considered. 80 Contributors RS and AH designed the protocol. RS completed the literature search and data synthesis. RS and AH interpreted the results. RS and AH wrote the manuscript.
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Fox No difference in DISCUS score between groups at T1. DISCUS score at T2 was increased in NC, SD, and 25D groupsgreatest increase observed in 25D group. DISCUS score at T2 decreased in the IN group. Significant correlation demonstrated between degree of dose reduction and DISCUS score (r=0.506, p<0.001)
Proportion with dyskinesia increased from 30% at T1 to 60% at T2 in the 25D group, did not change in the SD or NC groups, and fell from 60% to 20% in the IN group.
(1) (2) (3) Challenging behaviour frequency at followup lower than baseline in all 3 (100%) whose antipsychotic had been discontinued and in 15 (79%) of those who underwent dose reduction.
(1) Challenging behaviour (frequency counts)
Three groups described on basis of change in challenging behaviour: transient worsening (n=9, 39%), progressive improvement (n=5, 22%), persistent worsening (n=9, 39%)
(1) (4)
ID: severe-profound 100%
Comorbidities not reported
Thioridazine used in all participants completed discontinuation. Those in the progressive improvement group tended to receive lower initial doses of antipsychotic and have higher baseline levels of challenging behaviour (differences between groups not statistically significant, data not given). No change from baseline in group who discontinued antipsychotics (mean 6.4 to 6.5, p=0.76) 31% improved, 64% no change, 5% worse compared with baseline in group discontinuing antipsychotics Significant decrease in those who achieved discontinuation (mean 6.0 to 3.6, p=0.01).
Slight increase in those who achieved antipsychotic discontinuation (mean 2.8 to 3.0, statistical test not reported). 
Clinical factors
Higher baseline antipsychotic dose 47, 48, 57, 58 Higher baseline behavioural symptoms 47, 48, 57 Lower baseline behavioural symptoms 48 Higher baseline extrapyramidal symptoms 47 Higher baseline psychopathology 57, 59 Previous unsuccessful antipsychotic withdrawal attempt 46 Absence of co-administration of other psychoactive medication 39, 59 Setting/environmental factors Table 3 Factors shown to be associated with unsuccessful attempts to reduce or discontinue antipsychotic medication in people with ID taking antipsychotics for challenging behaviour
Panel 2 Future research directions
 High quality studies that investigate the feasibility of reduction or discontinuation of antipsychotics used for challenging behaviour in people with intellectual disability are needed.  Baseline characteristics of study participants should be well-defined and include screening for co-morbid mental illness using standardised instruments (such as the PAS-ADD) or adapted diagnostic criterial (such as the DC-LD).  To be useful in guiding management decisions, studies should be adequately powered to elucidate environmental and individual characteristics that are associated with successful and unsuccessful attempts to reduce or discontinue antipsychotic medication.  Although patient and caregiver attitude towards antipsychotic medication for challenging behaviour and concordance with treatment plans quite clearly influence their success, these were not mentioned in included studies, and should be investigated further.  The economic impact and change in resource use resulting from antipsychotic reduction or discontinuation for challenging behaviour is likely to be complex and will require the balancing of short-term risks (e.g. management of behavioural deterioration) against potential longer-term savings (e.g. in prescription costs and managing long-term adverse side-effects).  Novel or pragmatic study designs, possibly using routinely-collected health data, might be appropriate for further investigating this topic.
